Scholar Rock to Present at Upcoming Investor Conferences

November 3, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 3, 2026-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that management will participate in the following investor conferences:

- **UBS Global Biopharma Conference 2026**: Scholar Rock is scheduled to participate in a fireside chat at 10:00 a.m. GMT / 5:00 a.m. ET on Monday, November 16, 2026 in London.
- **Jefferies Global Healthcare Conference 2026**: Scholar Rock is scheduled to participate in a fireside chat at 4:00 p.m. GMT / 11:00 a.m. ET on Tuesday, November 17, 2026 in London.

A live webcast of the events will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcasts will be available for approximately 90 days.

About Scholar Rock
Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Following FDA approval in September 2026, Scholar Rock is commercializing ISEMBLYD (apitegromab-mstn) in the U.S. for people living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. The company plans to expand access to ISEMBYLD globally, in up to 50 countries worldwide.

As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more about our neuromuscular franchise at **ScholarRock.com** and follow @ScholarRock on X and on LinkedIn.

Scholar Rock® is a registered trademark and ISEMBLYD™ is a trademark of Scholar Rock, Inc.

Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X, or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261103507217/en/

Scholar Rock Contacts

Investors
Laura Ekas, Ph.D.
917-439-0374
ir@scholarrock.com

Media
Jeff Smith
682-401-8428
Molly MacLeod, Ph.D.
802-579-5995
media@scholarrock.com

Source: Scholar Rock